Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kreuter, J. Vansteenkiste, J. R. Fischer, W. Eberhardt, H. Zabeck, J. Kollmeier, M. Serke, N. Frickhofen, M. Reck, W. Engel-Riedel, S. Neumann, M. Thomeer, C. Schumann, P. De Leyn, T. Graeter, G. Stamatis, F. Griesinger, M. Thomas (Heidelberg, Loewenstein, Essen, Berlin, Hemer, Wiesbaden, Großhansdorf, Cologne, Göttingen, Ulm, Oldenburg, Germany; Leuven, Genk, Belgium). Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT. Eur Respir J 2014; 44: Suppl. 58, 1927

Member's Comments

No comment yet.

Related content which might interest you: A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Site of first progression (PR) differs between stage III NSCLC patients treated with simultaneous radiochemotherapy (RTCT) and those treated with radiotherapy (RT) alone following induction chemotherapy (CT) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Improved survival associated with neoadjuvant chemoradiation and surgery vs other means of treatment for NSCLC N2 patients (clinical stage IIIa and IIIb) Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Lung cancer risk prediction model based on data of the SOS trial (single center non-randomized lung cancer early detection trial) Source: International Congress 2014 – Risk assessment and tracheal reconstructions Year: 2014 Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Chemotherapy beyond 3rd line in NSCLC – A retrospective analysis Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC) Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 TTF 1- expression and pemetrexed based chemotherapy. A retrospective analysis Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Multicenter phase II trial of carboplatin (Cb) and gemcitabine (G) followed by concurrent chemoradiation (CRT) in patients with unresectable stage III non-small-cell-lung cancer (NSCLC): Cher@Nos trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 Biological dosimetry in lung cancer (LC) patients treated with fractionated radiotherapy (RT) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Randomized phase II study of adjuvant cisplatin/docetaxel (Cis-Doc) or cisplatin/vinorelbine (Cis-VRB) in patients (pts) with resected stage IB-II NSCLC: interim analysis Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 The role of second line chemotherapy in small cell lung cancer: A retrospective analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015